Among patients undergoing coronary stent placement with BMS and who tolerated 12 months of thienopyridine , continuing thienopyridine for an additional 18 months compared with placebo did not result in statistically significant differences in rates of stent thrombosis , MACCE , or moderate or severe bleeding .